Prilosec®
Omeprazole
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$20–40 (OTC brand)
With Insurance
$5–15
The Short Version
Plain-language summary
Prilosec (Omeprazole) shuts down the acid pumps in your stomach lining. This dramatically reduces stomach acid, which lets ulcers heal and stops acid reflux from damaging your esophagus.
How it works: Omeprazole permanently inactivates the proton pump, the molecular machine that secretes acid into the stomach. New pumps must be synthesized to restore acid production, which is why a drug with a 1-hour half-life can suppress acid for 72+ hours.
What people most commonly report
Step down gradually rather than stopping abruptly; dietary changes help ease transition
Check the evidence section for details on who funded the research.
What Else the Evidence Supports
Non-drug options with clinical backing
A 2-week elimination diet resolves symptoms in most GERD patients, PPIs treat the symptom while the cause continues
60–80% symptom resolution in 2–4 weeks; identify specific triggers.
Reduces nighttime reflux episodes by 50%+.
Significantly reduces nocturnal acid exposure.
Strong linear relationship between BMI and GERD symptoms.
What This Really Costs
Long-term cost projection based on current pricing
Monthly
$15
$10 w/ insurance
without insurance
Annual
$180
$120 w/ insurance
without insurance
10 Years
$1.8K
$1.2K w/ insurance
without insurance
30 Years
$5.4K
$3.6K w/ insurance
without insurance
Lifestyle alternative: $0/month in prescriptions. Elimination diet (trigger foods) - 60–80% symptom resolution in 2–4 weeks; identify specific triggers.
The average American retiree spends $165,000 on healthcare after retirement (Fidelity, 2024). Informed choices today compound over decades.
Related Evidence
Explore related medications reviewed on EvidentMeds
Metabolic & Lifestyle Alternatives
🥗 Dietary Changes Resolve Acid Reflux in 60–80% of Patients
A 2-week elimination diet resolves symptoms in most GERD patients, PPIs treat the symptom while the cause continues
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Elimination diet (trigger foods)
Remove coffee, alcohol, tomatoes, chocolate, citrus, fatty foods, mint
60–80% symptom resolution in 2–4 weeks; identify specific triggers
Elevate head of bed 6–8 inches
Use bed risers, not pillows
Reduces nighttime reflux episodes by 50%+
Time-restricted eating (stop 3hrs before bed)
No food within 3 hours of sleeping
Significantly reduces nocturnal acid exposure
Weight loss (5–10%)
Each 5% weight loss reduces GERD severity
Strong linear relationship between BMI and GERD symptoms
Probiotics (L. reuteri, L. rhamnosus)
Daily probiotic
Reduces regurgitation and GERD symptoms in RCTs
Global Prescribing & Pricing
PPIs are among the most overprescribed drug classes globally, US patients stay on them 5–10× longer than guidelines recommend
United States
$10–20 (generic OTC)/mo
Most patients prescribed indefinitely despite 4–8 week indication; 15% of US adults use PPIs
OTC availability means many patients self-prescribe indefinitely with no medical review
OTC available; prescription covered by most plans
United Kingdom
~$2–5 (NHS)/mo
Comparable prescribing volume but step-down mandated
NICE requires step-down from PPI to H2 blocker or on-demand use after 4–8 weeks; lifestyle counseling mandatory
Fully covered by NHS
France
~$3–8/mo
Lower chronic use, stricter reassessment requirements
HAS guidelines mandate reassessment at 4 weeks; lifestyle modification counseling documented at each renewal
Covered by Sécurité Sociale
Germany
~$5–12/mo
Step-down therapy standard practice
S3 guidelines require documented step-down attempt and lifestyle counseling before continuing beyond 8 weeks
Covered by GKV
Japan
~$8–18/mo
Lower GERD prevalence due to diet; PPIs used more acutely
H. pylori eradication is emphasized (very high H. pylori prevalence); dietary counseling integrated into GI care
Covered by JHIS
Germany's S3 guidelines require documented step-down therapy before extending PPI beyond 8 weeks. The UK's NICE mandates switching to on-demand use after the acute episode resolves. The US has no equivalent standard, producing a generation of permanent PPI users who were started on them for a 4–8 week condition.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid - they undergo the same FDA review - but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Key Efficacy Results
80–90% short-term acid suppression efficacy; intended for 4–8 weeks; most patients end up on indefinitely with no reassessment
Referenced Studies
Each study shows its evidence level and Cochrane RoB-2 risk-of-bias rating - tap the bias badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears", never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Omeprazole. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Omeprazole in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| Omeprazole vs H2 Blockers (ASTRONAUT) | PMID:9062047 | |
| PPI & Chronic Kidney Disease | PMID:26174986 | |
| PPI & Dementia Risk (JAMA) | PMID:26864376 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment - not a certified Cochrane review.
Our MethodologyCommon Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Headache
7%Usually resolves; if persistent, consider switching to an H2 blocker
Nausea / diarrhea
4%Take before first meal; usually self-resolving within days
Magnesium deficiency (long-term)
22%Annual magnesium blood test for users >1 year; supplement if needed
Vitamin B12 deficiency (long-term)
18%Annual B12 test for users >2 years; supplement sublingually
C. difficile infection risk
1.7× increasedAvoid PPIs during and after antibiotics if possible; use probiotics
Rebound acid on stopping
40%+Step down gradually rather than stopping abruptly; dietary changes help ease transition
Serious Adverse Effects
- • Chronic kidney disease, long-term PPI use independently associated with CKD progression
- • Increased risk of dementia, observational data; monitor annually if >5 years of use
- • Bone fracture risk, PPIs reduce calcium absorption; annual bone density for long-term users >50
- • Hypomagnesemia (severe), can cause seizures and cardiac arrhythmias if undetected
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician - do not wait for your next scheduled appointment.
Contact soon if you notice
- Chronic kidney disease, long-term PPI use independently associated with CKD progression
- Increased risk of dementia, observational data; monitor annually if >5 years of use
- Bone fracture risk, PPIs reduce calcium absorption; annual bone density for long-term users >50
- Hypomagnesemia (severe), can cause seizures and cardiac arrhythmias if undetected
- Difficulty swallowing (dysphagia)
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups - discuss with your provider before use.
Use only if benefit outweighs risk; limited human data.
Excreted in breast milk; consider alternatives for mild symptoms.
Estrogen and progesterone affect how well the valve between the esophagus and stomach closes. After menopause, changes in this valve and GI motility can worsen acid reflux. Dietary changes, weight management, and sleep positioning often help significantly before reaching for a daily PPI.
Use for shortest duration possible; pediatric GERD often resolves with dietary modification.
Higher risk of C. diff, fractures, B12 deficiency, and kidney disease. Reassess need every 6 months.
Long-term PPI use independently associated with CKD progression; monitor eGFR annually.
Hepatic impairment reduces omeprazole clearance; max 20mg/day in severe cases.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences - anonymous & anecdotal
Join the Conversation
Premium subscribers can share their experience and confirm others' reports.
Cancel anytime.
Stopping This Medication Safely
Abruptly stopping PPIs causes rebound acid hypersecretion, the stomach overproduces acid for 2–4 weeks, often causing symptoms worse than the original GERD. This leads many patients to restart unnecessarily. A gradual taper prevents this cycle.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents, it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Research supports stepping down to every-other-day dosing for 2 weeks before stopping completely
- ·Switching to an H2 blocker (famotidine/Pepcid) for 2–4 weeks as a bridge is a documented clinical approach
- ·Research supports implementing dietary changes (eliminating triggers) 1–2 weeks before reducing the dose
- ·Calcium carbonate (Tums) or sodium bicarbonate are documented for breakthrough symptoms during the stopping process
- ·Research documents rebound acid symptoms in weeks 1–2; this is a documented pharmacological effect and does not necessarily indicate treatment needs to be restarted
Warning Symptoms, Contact Your Doctor If You Experience:
- Difficulty swallowing (dysphagia)
- Black or bloody stools (possible ulcer bleeding)
- Unexplained weight loss with reflux symptoms
- Pain radiating to back or severe chest pain
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
$2.99, printable guide for your next appointment
Questions to Ask
- 1.Do I actually need this long-term, or was it started for a short-term reason?
- 2.Can we try stepping down to an H2 blocker or on-demand use?
- 3.Should we test for H. pylori before assuming I need ongoing acid suppression?
- 4.Am I being monitored for B12, magnesium, and kidney function annually?
- 5.What dietary changes would you recommend to reduce or eliminate this medication?
Lab Tests to Request
- H. pylori test (breath or stool antigen)
- Vitamin B12 level
- Serum magnesium
- Kidney function (eGFR), annually for long-term users
- Bone density if on PPIs >5 years
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Get notified when we update Prilosec®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.
Found this useful?
Help keep EvidentMeds editorially independent and community supported. Every dollar funds transparent medication data.